Screener
Rigel Pharmaceuticals RIGL EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Provision for income taxes | 3,003 | 65 |
| Net income | $8,654 | $11,446 |
| Net income per share | ||
| Basic | $0.47 | $0.64 |
| Diluted | $0.44 | $0.63 |
| Weighted average shares used in computing net income per share | ||
| Basic | 18,412 | 17,808 |
| Diluted | 19,686 | 18,169 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's EPS (diluted)?
- Rigel Pharmaceuticals (RIGL) reported EPS (diluted) of $0.44 in Q1 2026.
- How has Rigel Pharmaceuticals's EPS (diluted) changed year-over-year?
- Rigel Pharmaceuticals's EPS (diluted) decreased by 30.2% year-over-year, from $0.63 to $0.44.
- What is the long-term trend for Rigel Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's EPS (diluted) has grown at a 256.9% compound annual growth rate (CAGR), from -$0.12 to $19.47.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Rigel Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude